BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)

Background: Phase 2 data for the combination of ENCO (a selective BRAF inhibitor)+ CTX (an anti-EGFR antibody) in pts with BRAF V600E mCRC showed the regimen was well tolerated and improved response rate, progression-free survival, and overall survival compared with historical controls. BEACON CRC (NCT02928224) is a randomized phase 3 study evaluating both the triplet combination BINI (a MEK inhibitor)+ ENCO+ CTX and the doublet combination ENCO+ CTX compared with investigators’ choice of irinotecan (IRI)+ CTX or FOLFIRI (folinic acid, 5-fluorouracil, and IRI)+ CTX in pts with BRAF V600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. Here we describe the results of the SLI to determine the safety of the triplet combination.Methods: Nine pts with...© European Society for Medical Oncology 2017. Published by Oxford University Press. All rights …